-
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
16 Apr 2024 20:01 GMT
… , acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating … www.kiniksa.com. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every …
-
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
02 Apr 2024 11:30 GMT
… 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) … 2b trial designed to evaluate the treatment response … , and commercializing therapeutic medicines for patients suffering from … release. ARCALYST is a registered trademark of Regeneron. All …
-
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
28 Feb 2024 12:30 GMT
… trial are intended to inform trial … -stage clinical trials across multiple … Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug … doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
Medicines …
-
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript
29 Feb 2024 14:49 GMT
… years post approval of ARCALYST for the treatment of recurrent pericarditis … to provide life-changing medicines for patients and building … &A Session Follow Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) Follow … through to around 11,000 doctors. So that’s a …
-
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
21 Feb 2024 21:01 GMT
… , acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating … www.kiniksa.com. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every …
-
Bank of New York Mellon Corp Grows Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)
05 Feb 2024 11:04 GMT
… Kiniksa Pharmaceuticals
Insider Transactions at Kiniksa Pharmaceuticals
In … unmet medical needs worldwide. Its product candidates include ARCALYST, … Phase II clinical trials for the treatment of giant … 2b clinical trial for the treatment of prurigo nodularis …
-
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2023 Earnings Call Transcript
03 Feb 2024 13:57 GMT
… the Center for Medicare and Medicaid Services assigned a … approval had no FDA-approved treatments. Nearly 25,000 … in our share of ARCALYST profit from Kiniksa. … Session Follow Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Follow Regeneron Pharmaceuticals Inc. …
-
Los Angeles Capital Management LLC Cuts Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)
29 Jan 2024 12:53 GMT
…
About Kiniksa Pharmaceuticals
(Free Report)
Kiniksa Pharmaceuticals, Ltd., … unmet medical needs worldwide. Its product candidates include ARCALYST, … Phase II clinical trials for the treatment of giant … 2b clinical trial for the treatment of prurigo nodularis …
-
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Down 12.5% in December
18 Jan 2024 11:17 GMT
… Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company … unmet medical needs worldwide. Its product candidates include ARCALYST, … Phase II clinical trials for the treatment of giant … 2b clinical trial for the treatment of prurigo nodularis …
-
Hennion & Walsh Asset Management Inc. Purchases 26,002 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)
14 Jan 2024 15:31 GMT
… stock.
Kiniksa Pharmaceuticals Profile
(Free Report)
Kiniksa Pharmaceuticals, Ltd., … unmet medical needs worldwide. Its product candidates include ARCALYST, … II clinical trials for the treatment of giant … 2b clinical trial for the treatment of prurigo …